We believe great partnerships create great possibilities and are inspired by our partners
As a global biopharmaceutical company, we leverage our agility, R&D capabilities and global footprint to develop valuable business partnerships that fuel tomorrow’s breakthrough discoveries across our three therapeutic areas: Oncology, Rare Disease and Neuroscience. External innovation is at the heart of our strategy. We believe in the expertise of our partners and value the opportunity to collaborate, bringing our skills, experience and global reach to accelerate innovation to bring new medicines to patients.
Exclusively sourcing our pipeline through external innovation, we have no internal competing pipeline as we recognize the best science is delivered in biotech and academic institutions. We are proud our team comprises talents attracted from Pharma, biotech and academia, to drive shared success through creative collaborations.
We have the tenacity
to carry your innovations forward
Ipsen Key Facts
Impact across the globe
Represented in 88 countries, our commercial sales have strong coverage across North America (33%), Europe (40%), and the rest of world (27%) with our medicines showing best-in-class commercial performance.
Our North America base has grown rapidly: 600% over the last 6 years reaching >$1bn in 2022.
Strength in numbers: a strong pipeline
Since 2020, Ipsen has brought in over 20 best- or first-in-class programs across our pipeline at every stage of development and plans are in place to acquire more.
We are focused. We invest in opportunities in challenging disease areas to better address challenges faced by the community.
Acquiring Epizyme & Tazverik®
Ipsen acquired Epizyme in 2022, and with it Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor, strengthening our oncology pipeline and reinforcing our focus on solid tumors and hematological malignancies.
Integrating Albireo & Bylvay®
In 2023, Ipsen acquired Albireo, accelerating our growth in rare disease with treatments for pediatric liver diseases. With Bylvay® (odevixibat), we boost our expertise in treating pruritus in young people with progressive familial intrahepatic cholestasis (PFIC). With Bylvay® (odevixibat) we boost our expertise in rare liver diseases in progressive familial intrahepatic cholestasis (PFIC) and Alagille Syndrome. The Phase III BOLD study in Biliary Atresia remains ongoing. This partnership also results in a number of other assets joining our clinical pipeline.
Recognition on the global stage
Ipsen was named SCRIP’s 2023 BD Team of the Year and 2022 Pharma BD Team of the year at the European Lifestars Award.
Focused and fast
Guided by our strategy, we move fast to make deals with like-minded partners. That’s how we were able to make two acquisitions in less than nine months.
Contact the partnering team
At Ipsen, entering partnerships is always personal. Our team is committed to success and has the expertise to deliver it. Contact us to see how together, we can accelerate innovation for patients.
Throughout the year, Ipsen holds numerous events for and with partners. Look through our upcoming events if you are interested in our work and in partnering with us and would like to meet our team.
Top stories in partnering
FY 2023 results announcement
Ipsen’s FY 2023 results announcement took place on 8 February 2024 at 7am CET/1am EST.
Ipsen sponsors 5 elite athletes on their journeys to the 2024 Paralympics
Starting now and throughout 2024, Ipsen is sponsoring five talented, elite athletes on their journeys toward the 2024 Paralympic Games.
Examining the European Pharma legislation: EFPIA publishes the Dolon Report
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has commissioned Dolon to develop a report to assess the impact of the proposed European Commission pharma legislation. The Dolon Report, published on 6 November, has projected that the proposed legislation…
Capital Markets Day 2023
Ipsen plans to host a capital-markets day, starting at 12.30 pm GMT on 7 December 2023, at The Brewery, London. In-person attendance is by invitation only.
2023 year to date and third-quarter sales results
Ipsen has published its year to date and third-quarter sales results on 26 October 2023 at 7am CET.
Winner of Ipsen’s golden ticket announced as newest resident of Biolabs Hôtel Dieu
We are pleased to announce that Hemerion has been awarded Ipsen’s golden ticket 2023, receiving a year’s free lab space at the brand new, cutting-edge facility in the heart of Paris, France, close to Notre-Dame, at Paris Hôpital Hotel Dieu, AP-HP.
David Loew, Philippe Lopes Fernandes inaugurate Biolabs – Hôtel Dieu
Biolabs, a new biotech incubator located in the historic Hôtel Dieu, was inaugurated on 6 July 2023. As a founding sponsor of the initiative, Ipsen was represented at the event by CEO David Loew and Chief Business Officer Philippe Lopes…
Ipsen’s 2022 Integrated Annual Report now available
2022 was a year of focus, momentum and growth at Ipsen. Learn about the progress we made and download the 2022 Integrated Annual Report here.
Applications now open for the 2023 Golden Ticket Competition
As part of our commitment to accelerating transformative research and development, we’re excited to announce that our Golden Ticket Competition is now open! Through our continued partnership with Biolabs, we’re delighted to be offering the brightest minds in biotech a…
Ipsen anti-corruption system certification renewed in 2022
In December 2021, Ipsen received ISO 37001 certification for its anti-corruption management systems by Eurocompliance, a certification organization dedicated to the prevention of corruption.